DrugPatentWatch Database Preview

Ge Healthcare Company Profile

GE HEALTHCARE has fifty-three approved drugs.

There are seven US patents protecting GE HEALTHCARE drugs.

There are one hundred and sixteen patent family members on GE HEALTHCARE drugs in thirty-two countries and one hundred supplementary protection certificates in seventeen countries.

International Patents:	116
US Patents:	7
Tradenames:	61
Ingredients:	41
NDAs:	53
Drug Master File Entries:	5
Patent Litigation for Ge Healthcare:	See patent lawsuits for Ge Healthcare

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ge Healthcare	HYPAQUE	diatrizoate meglumine	INJECTABLE;INJECTION	016403-001	Approved Prior to Jan 1, 1982		DISCN	No	No		Start Trial				Start Trial
Ge Healthcare	MPI DTPA KIT - CHELATE	technetium tc-99m pentetate kit	INJECTABLE;INJECTION	017255-001	Approved Prior to Jan 1, 1982		DISCN	No	No		Start Trial				Start Trial
Ge Healthcare	HYPAQUE	diatrizoate meglumine	INJECTABLE;INJECTION	016403-002	Approved Prior to Jan 1, 1982		DISCN	No	No		Start Trial				Start Trial
Ge Healthcare	INDIUM IN 111 OXYQUINOLINE	indium in-111 oxyquinoline	INJECTABLE;INJECTION	019044-001	Dec 24, 1985		RX	Yes	Yes		Start Trial				Start Trial
Ge Healthcare	HYPAQUE	diatrizoate sodium	FOR SOLUTION;ORAL, RECTAL	011386-001	Approved Prior to Jan 1, 1982		DISCN	No	No		Start Trial				Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Ge Healthcare	VISIPAQUE 270	iodixanol	INJECTABLE;INJECTION	020808-001	Aug 29, 1997	4,278,654	Start Trial
Ge Healthcare	INDIUM IN 111 OXYQUINOLINE	indium in-111 oxyquinoline	INJECTABLE;INJECTION	019044-001	Dec 24, 1985	4,335,095	Start Trial
Ge Healthcare	VISIPAQUE 270	iodixanol	INJECTABLE;INJECTION	020808-001	Aug 29, 1997	5,366,722	Start Trial
Ge Healthcare	OMNISCAN	gadodiamide	INJECTABLE;INJECTION	020123-001	Jan 8, 1993	4,687,659	Start Trial
Ge Healthcare	OMNISCAN	gadodiamide	INJECTABLE;INJECTION	022066-002	Sep 5, 2007	5,362,475	Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Subscribe to access the full database, or Start Trial
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0579826	SPC/GB02/042	United Kingdom	Start Trial	PRODUCT NAME: ERTAPENEM ((1R,5S,6S,8R,2'S,4'S)-2-(2-(3-CARBOXYPHENYLCARBAMOYL)PYRROLIDIN-4-YLTHIO)-6-(1-HYDROXYETHYL)-1-METHYLCARBAPENEM-3-CARBOXYLIC ACID), A PHARMACEUTICALLY ACCEPTABLE SALT OR IN VIVO HYDROLYSABLE ESTER THEREOF, ESPECIALLY AS THE MONOSODIUM SALT ERTA; REGISTERED: UK EU/1/02/216/001 20020422
0933372	SPC/GB08/018	United Kingdom	Start Trial	PRODUCT NAME: FOSAMPRENAVIR CALCIUM: ((1S,2R)-3-(((4-AMINOPHENYL)SULFONYL)(2-METHYLPROPYL)AMINO)-1-(PHENYLMETHYL)-2(PHOSPHONOOXY)PROPYL)-CARBABAMIC ACID C-((3S)-TETRAHYDRO-3-FURANYL) ESTER CALCIUM SALT; REGISTERED: UK EU/1/04/282/001 20040712; UK EU/1/04/282/002 20040712
0806968	SPC/GB07/011	United Kingdom	Start Trial	PRODUCT NAME: GADOFOSVESET TRISODIUM; REGISTERED: UK EU/1/05/313/001 20051003; UK EU/1/05/313/002 20051003; UK EU/1/05/313/003 20051003; UK EU/1/05/313/004 20051003; UK EU/1/05/313/005 20051003; UK EU/1/05/313/006 20051003; UK EU/1/05/313/007 20051003; UK EU/1/05/313/008 20051003; UK EU/1/05/313/009 20051003
1611115	C20150004 00139	Estonia	Start Trial	PRODUCT NAME: FLUTEMETAMOOL (18F);REG NO/DATE: EU/1/14/941 26.08.2014
0961612	09C0050	France	Start Trial	PRODUCT NAME: PACLITAXEL ALBUMINE; REGISTRATION NO/DATE: EU/1/07/428/001 20080111
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.